Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propoxycaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 6/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 6/20 | 1.00 |
| ▸ | SCN3A known ✓ | Q9NY46 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | MAOA | P21397 | 3/20 | 0.67 |
| ▸ | HTR3A | P46098 | 3/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propoxycaine SCHEMBL29353209 | 1.00 | SCN1A (1.00) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL24720 | 0.99 | SCN1A (0.98) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL1651061 | 0.98 | SCN1A (0.95) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL82280 | 0.95 | SCN1A (0.91) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL1007224 | 0.94 | CYP2D6 (0.88) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Propoxycaine SCHEMBL8683800 | 0.91 | CYP1A2 (0.83) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL14304166 | 0.89 | CYP1A2 (0.80) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL22987103 | 0.88 | CYP1A2 (0.78) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| SCHEMBL5925620 | 0.87 | CYP2D6 (0.77) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 | |
| Ambucaine SCHEMBL3660746 | 0.87 | SCN1A (0.76) | SCN1ASCN2ASCN3ACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5693 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| US-20260137637-A1 | ANESTHETIC AGENT MICRO AND NANO PARTICLES, AND METHODS OF MAKING AND USING THE SAME | HAAS ERIC (US) | 2026-05-21 | — | — | US | claimed |
| US-12622873-B2 | Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-12 | — | — | US | claimed |
| US-20260115156-A1 | INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT | UNIV KOREA RES & BUS FOUND (KR) | 2026-04-30 | — | — | US | claimed |
| US-20260083666-A1 | METHOD OF TREATING DISEASE | CREWS THOMAS M (US) | 2026-03-26 | — | — | US | claimed |
| EP-4436552-B1 | GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC | OREXA B V (NL) | 2026-02-04 | — | — | EP | claimed |
| US-12527756-B2 | Anesthetic agent micro and nano particles, and methods of making and using the same | HAAS ERIC (US) | 2026-01-20 | — | — | US | claimed |
| WO-2025235864-A1 | COATED NEEDLE ADMINISTRATION SYSTEMS | EVOLUS, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250319025-A9 | COMPOSITIONS COMPRISING MODIFIED PHOSPHOLIPIDS AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-16 | — | — | US | claimed |
| EP-4578441-A1 | TREATMENT OF LOCALIZED PAIN | PlantTec Medical GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| US-4560553-A | THERAPEUTIC, COSMETIC;MIXTURES OF HYPOTENSIVES, ANESTHETICS, BETA-BLOCKERS AND MICROBIOCIDES | MERCK & CO., INC. (US) | 1985-12-24 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| US-4495174-A | TIME-RELEASE AGENTS | RESEARCH CORPORATION (US) | 1985-01-22 | — | — | US | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4041174-A | INJECTING AN ESTER LOCAL ANESTHETIC | ROM-AMER PHARMACEUTICALS, LTD. (US) | 1977-08-09 | — | — | US | claimed |
| US-4029794-A | SAXITOXIN | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1977-06-14 | — | — | US | claimed |
| US-4022899-A | TETRODOXIN, DESOXYTETRODOXIN, AMINOALKYL BENZOATE | ASTRA PHARMACEUTICAL PRODUCTS, INC. (US) | 1977-05-10 | — | — | US | claimed |